MA32384B1 - Association pharmacologique - Google Patents

Association pharmacologique

Info

Publication number
MA32384B1
MA32384B1 MA33401A MA33401A MA32384B1 MA 32384 B1 MA32384 B1 MA 32384B1 MA 33401 A MA33401 A MA 33401A MA 33401 A MA33401 A MA 33401A MA 32384 B1 MA32384 B1 MA 32384B1
Authority
MA
Morocco
Prior art keywords
diseases
relates
pharmaceutical compositions
fibrosis
apoptosis
Prior art date
Application number
MA33401A
Other languages
Arabic (ar)
English (en)
Inventor
Martin Friedrich Stefanic
Frank Hilberg
Rolf Kaiser
David Shapiro
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40912046&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32384(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32384B1 publication Critical patent/MA32384B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)

Abstract

La présente invention concerne une association médicamenteuse qui peut s'avérer utile pour le traitement de maladies donnant lieu à prolifération cellulaire, à migration ou apoptose des cellules myélomateuses, à angiogenèse ou à fibrose. L'invention concerne également un procédé destiné au traitement de ces maladies et consistant en une administration simultanée, séparée, ou séquentielle, de quantités suffisantes de principes actifs spécifiques et/ou un co-traitement avec radiothérapie, dans des proportions engendrant un effet cumulatif et synergique. L'invention concerne enfin l'utilisation de ces composés spécifiques et/ou de la radiothérapie pour la fabrication des préparations des associations médicamenteuses considérées.
MA33401A 2008-06-06 2010-12-06 Association pharmacologique MA32384B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08157749 2008-06-06
US7888208P 2008-07-08 2008-07-08
PCT/EP2009/056891 WO2009147218A1 (fr) 2008-06-06 2009-06-04 Association pharmacologique

Publications (1)

Publication Number Publication Date
MA32384B1 true MA32384B1 (fr) 2011-06-01

Family

ID=40912046

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33401A MA32384B1 (fr) 2008-06-06 2010-12-06 Association pharmacologique

Country Status (34)

Country Link
US (5) US20110178099A1 (fr)
EP (2) EP2293795B1 (fr)
JP (2) JP5993573B2 (fr)
KR (1) KR101760657B1 (fr)
CN (1) CN102056609B (fr)
AR (1) AR072061A1 (fr)
AU (1) AU2009254554B2 (fr)
CA (1) CA2726644C (fr)
CO (1) CO6280488A2 (fr)
CY (2) CY1116877T1 (fr)
DK (2) DK2985025T3 (fr)
EA (1) EA020046B1 (fr)
EC (1) ECSP10010716A (fr)
ES (2) ES2552238T3 (fr)
HK (1) HK1152640A1 (fr)
HR (2) HRP20151186T1 (fr)
HU (2) HUE025821T2 (fr)
IL (1) IL208953B (fr)
LT (1) LT2985025T (fr)
MA (1) MA32384B1 (fr)
ME (1) ME02273B (fr)
MX (1) MX338047B (fr)
MY (1) MY158929A (fr)
NZ (1) NZ588957A (fr)
PE (1) PE20100084A1 (fr)
PL (2) PL2985025T3 (fr)
PT (2) PT2293795E (fr)
RS (2) RS54293B1 (fr)
SI (2) SI2985025T1 (fr)
TW (1) TWI447113B (fr)
UA (1) UA102258C2 (fr)
UY (1) UY31866A (fr)
WO (1) WO2009147218A1 (fr)
ZA (1) ZA201007594B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
DK2299987T3 (en) 2008-06-06 2018-05-22 Boehringer Ingelheim Int Pharmaceutical Capsule Dosage Form Containing A Suspension Formulation Of An Indolinone Derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CA3172586A1 (fr) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Composes d'imatinib en aerosol et utilisations connexes
EP3365180B1 (fr) * 2015-10-21 2019-12-18 Capsugel Belgium NV Procédé d'impression pour des formes pharmaceutiques orales

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96531A (en) * 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
WO2005070469A1 (fr) * 2004-01-23 2005-08-04 Sarissa, Inc. Techniques de traitement du mesotheliome au moyen d'un oligonucleotide antisens d'une thymidylate synthase
WO2001014379A2 (fr) * 1999-08-23 2001-03-01 Eli Lilly And Company Nouvelle forme cristalline de disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l- sel d'acide glutamique et procedes de preparation
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
WO2006023010A1 (fr) * 2004-08-18 2006-03-02 Salmedix, Inc. Formulations d'alanosine et procedes d'utilisation
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (fr) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Traitement du cancer
EP1870400A1 (fr) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Sels et sels cristallines d'un produit 2-indolinone
JP2008543975A (ja) * 2006-08-14 2008-12-04 シコール インコーポレイティド 高度に純粋なペメトレキセド二酸およびその調製方法

Also Published As

Publication number Publication date
IL208953A0 (en) 2011-01-31
EA201001853A1 (ru) 2011-06-30
EP2985025B1 (fr) 2018-01-17
AU2009254554A1 (en) 2009-12-10
TWI447113B (zh) 2014-08-01
MX2010012937A (es) 2011-02-25
JP2011522008A (ja) 2011-07-28
RS57035B1 (sr) 2018-05-31
TW201002690A (en) 2010-01-16
US20110178099A1 (en) 2011-07-21
US20130237549A1 (en) 2013-09-12
EA020046B1 (ru) 2014-08-29
DK2985025T3 (en) 2018-03-19
UA102258C2 (en) 2013-06-25
DK2293795T3 (en) 2015-10-19
LT2985025T (lt) 2018-04-10
IL208953B (en) 2018-03-29
WO2009147218A1 (fr) 2009-12-10
HUE025821T2 (en) 2016-04-28
PT2985025T (pt) 2018-03-15
ES2552238T3 (es) 2015-11-26
CO6280488A2 (es) 2011-05-20
US20180243308A1 (en) 2018-08-30
JP2015007143A (ja) 2015-01-15
HRP20180602T1 (hr) 2018-05-18
ECSP10010716A (es) 2011-02-28
AR072061A1 (es) 2010-08-04
AU2009254554B2 (en) 2015-08-20
CA2726644A1 (fr) 2009-12-10
MY158929A (en) 2016-11-30
SI2293795T1 (sl) 2015-12-31
ES2662824T3 (es) 2018-04-09
KR20110025172A (ko) 2011-03-09
RS54293B1 (en) 2016-02-29
UY31866A (es) 2010-01-29
HUE037291T2 (hu) 2018-08-28
CY1120505T1 (el) 2019-07-10
CA2726644C (fr) 2018-02-06
HK1152640A1 (en) 2012-03-09
EP2293795B1 (fr) 2015-08-12
EP2293795A1 (fr) 2011-03-16
US20160250218A1 (en) 2016-09-01
MX338047B (es) 2016-03-31
ME02273B (me) 2016-02-20
EP2985025A1 (fr) 2016-02-17
PL2985025T3 (pl) 2018-06-29
US20150174126A1 (en) 2015-06-25
ZA201007594B (en) 2011-07-27
CN102056609B (zh) 2012-12-05
JP5993573B2 (ja) 2016-09-14
HRP20151186T1 (hr) 2015-12-04
SI2985025T1 (en) 2018-04-30
NZ588957A (en) 2013-03-28
KR101760657B1 (ko) 2017-07-24
CN102056609A (zh) 2011-05-11
CY1116877T1 (el) 2017-04-05
PE20100084A1 (es) 2010-02-05
PT2293795E (pt) 2015-11-17
PL2293795T3 (pl) 2016-01-29

Similar Documents

Publication Publication Date Title
MA32384B1 (fr) Association pharmacologique
Blakaj et al. Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data
MXPA05011656A (es) Combinaciones para el tratamiento de enfermedades que implican proliferacion, migracion o apoptosis celulares de celulas de mieloma, o angiogenesis.
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
GB2467670A (en) Chemical entities and therapeutic uses thereof
BRPI1014978A2 (pt) método de tratamento do câncer e composição farmacêutica.
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
BRPI0507048A (pt) uso de baixa dosagem de eritropoetina para estimular células precursoras endoteliais, regenerar órgãos e retardar a progressão de danos em órgão alvo
BRPI0710671B8 (pt) uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa
BRPI1010861A8 (pt) métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica
NZ599439A (en) Compositions and methods for treating centrally mediated nausea and vomiting
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
WO2014160216A3 (fr) Agents anticancéreux à double ciblage
EP3818991A3 (fr) Compositions et procédés de traitement de maladies
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
MX2010009270A (es) Compuestos y metodos para la prevencion o tratamiento de reestenosis.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
NO20064753L (no) Kombinasjonsterapi